doi:10.1172/JCI116842
The only published human data are from 12 patients with interstitial cystitis (2024) and 2 healthy subjects (2026)
This aligns naturally with quality management principles emphasizing defined responsibilities and authorities (Article 14, EU AI Act)
However, like all injectables, some individuals may experience: Always consult your medical provider before starting treatment
Before human translation, essential parameters to define: optimal dosing, infusion/administration route, frequency, biomarkers to monitor (senescent cell burden, inflammatory cytokines, organ function), long-term follow-up for adverse outcomes (especially tumour risk)
This compound is not approved by the FDA or any regulatory authority and is intended solely for laboratory research purposes